Dublin, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Pain Management Market - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The Cancer Pain Management Market grew from USD 7.86 billion in 2024 to USD 8.35 billion in 2025. It is expected to continue growing at a CAGR of 6.13%, reaching USD 11.24 billion by 2030.
The cancer pain management market is advancing steadily, shaped by a convergence of clinical, technological, and regulatory developments. Senior executives navigating this sector face evolving challenges and opportunities as therapeutic approaches and supply chains adapt to dynamic patient needs and policy landscapes.
Key Takeaways for Decision-Makers
- Demand for patient-centric and integrative pain management therapies is rising, reflecting a shift toward protocols that address both tumor-related and neuropathic pain.
- Regulatory advancements have catalyzed the market introduction of targeted agents and combination therapies, expediting approvals and expanding treatment options.
- Non-invasive administration routes and sophisticated delivery systems have strengthened patient adherence and outcomes, particularly in outpatient and home care settings.
- Stakeholder collaboration, including alliances between pharmaceutical firms and specialty organizations, enhances research pipelines and accelerates time to market for novel therapies.
- Digital tools and real-time data analytics are being integrated into pain protocols, supporting early intervention, value-based reimbursement, and improved clinical decision-making.
Scope & Segmentation of the Cancer Pain Management Market
- Drug Classes: Adjuvant analgesics (including anticonvulsants, antidepressants, corticosteroids), local anesthetics, NSAIDs, and opioids (natural, semi-synthetic, synthetic).
- Routes of Administration: Oral (capsules, solutions, tablets), parenteral (intramuscular, intravenous, subcutaneous), sublingual (films, lozenges), and transdermal.
- Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy.
- End Users: Cancer institutes, home care, and hospitals.
- Applications: Bone metastasis pain, neuropathic pain, and visceral pain.
Why This Report Matters
- Enables strategic planning by illustrating evolving trends, competitive shifts, and regulatory impacts in cancer pain management.
- Supports market entry and expansion by aligning commercial strategies with regional dynamics, reimbursement models, and stakeholder expectations.
- Guides procurement, investment, and R&D prioritization with robust segmentation, technology, and supply chain analysis.
Companies Featured
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson
- Pfizer Inc.
- Viatris Inc.
- Endo International plc
- Hikma Pharmaceuticals PLC
- Grunenthal GmbH
- Mallinckrodt Pharmaceuticals
- Purdue Pharma L.P.
- Mayne Pharma Group Ltd.
Conclusion
Cancer pain management is entering a period of significant evolution, with technology, regulatory initiatives, and patient needs driving transformation. Senior executives equipped with these insights will be well positioned to anticipate market shifts and make informed, strategic decisions for sustainable growth.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 189 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value (USD) in 2025 | $8.35 Billion |
| Forecasted Market Value (USD) by 2030 | $11.24 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Pain Management Market, by Drug Class
8.1. Introduction
8.2. Adjuvant Analgesics
8.2.1. Anticonvulsants
8.2.2. Antidepressants
8.2.3. Corticosteroids
8.3. Local Anesthetics
8.4. Nsaids
8.5. Opioids
8.5.1. Natural
8.5.2. Semi-Synthetic
8.5.3. Synthetic
9. Cancer Pain Management Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsules
9.2.2. Solutions
9.2.3. Tablets
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
9.4. Sublingual
9.4.1. Films
9.4.2. Lozenges
9.5. Transdermal
10. Cancer Pain Management Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Cancer Pain Management Market, by End User
11.1. Introduction
11.2. Cancer Institutes
11.3. Home Care
11.4. Hospitals
12. Cancer Pain Management Market, by Application
12.1. Introduction
12.2. Bone Metastasis Pain
12.3. Neuropathic Pain
12.4. Visceral Pain
For more information about this report visit https://www.researchandmarkets.com/r/8nmt4w
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
